AstraZeneca PLC (LON:AZN) target price held steady at 5,100.00GBX, reported today by Liberum Capital
- Updated: March 20, 2017
Yesterday AstraZeneca PLC (LON:AZN) traded 0.64% higher at 4,870.00GBX. The company’s 50-day moving average is 4,590.99GBX and its 200-day moving average is 4,607.83GBX. The last stock close price is up 6.28% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 4,469,010 shares of the stock were exchanged, up from an average trading volume of 2,765,280
AstraZeneca PLC (LON:AZN) had its target price hold steady to 5,100.00GBX by Liberum Capital in a report released 03/20/2017. The new target price indicates a possible upside of 0.05% based on the company's last stock close price.
Previously on 3/17/2017, Liberum Capital reported about AstraZeneca PLC (LON:AZN) held steady the target price at 5,100.00GBX. At the time, this indicated a possible upside of 0.06%.
See Chart Below
AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a P/E ratio of 17.74 The company’s market cap is currently 0 GBX.
In addition to Liberum Capital reporting its target price, a total of 29 equity analysts have released a ratings update on AZN. The one year target is 61.96GBX with four equity analysts rating the company a strong buy, fourteen equity analysts rating the company a buy, thirteen equity analysts rating the company a hold, two equity analysts rating the company a underperform, and lastly one equity analyst rating the company a sell.
Brief Synopsis About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.